Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

In our MTB, WES enabled some additional clinically highly actionable recommendations for selected patients, suggesting that some patients do benefit from additional WES. These recommendations were often related to complex biomarkers, which may in principle also be derived from larger panels. These findings should be re-investigated prospectively in larger cohorts.

Authors

Maike Collienne (ORCID: https://orcid.org/0000-0003-0932-2471)
Frederik Marmé (ORCID: https://orcid.org/0000-0002-6591-3367)
Thomas Michaeli
Sonja Loges (ORCID: https://orcid.org/0000-0002-7650-8527)
Matthias Ebert (ORCID: https://orcid.org/0000-0002-0910-0652)
Johannes Betge (ORCID: https://orcid.org/0000-0001-9549-1866)
Christoph Brochhausen (ORCID: https://orcid.org/0000-0002-6761-0247)
Alexander Streuer (ORCID: https://orcid.org/0000-0002-3531-534X)
Volker Ast (ORCID: https://orcid.org/0009-0008-7318-0301)
Melanie Janning (ORCID: https://orcid.org/0000-0002-6632-8506)
Daniel Nowak (ORCID: https://orcid.org/0000-0001-7130-7921)
R. Lozynskyy (ORCID: https://orcid.org/0000-0002-4562-8438)
Fabian Siegel (ORCID: https://orcid.org/0000-0002-9673-5030)
Tobias Boch (ORCID: https://orcid.org/0000-0001-8588-4180)
Verena Haselmann (ORCID: https://orcid.org/0000-0002-8380-6581)
Jan Kirchhof (ORCID: https://orcid.org/0000-0001-8576-4787)
Michael Neumaier (ORCID: https://orcid.org/0000-0003-0410-3931)
Marc Sütterlin (ORCID: https://orcid.org/0000-0003-0205-2552)
Andreas Teufel (ORCID: https://orcid.org/0000-0001-7953-8927)
Eva Krieghoff‐Henning (ORCID: https://orcid.org/0000-0001-8381-3100)
C. Sauer
Christina Cotarelo
W-K Hofmann

Institutions

University of Mannheim (DE)
German Cancer Research Center (DE)
Heidelberg University (DE)
University Hospital Heidelberg (DE)
National Center for Tumor Diseases (DE)
University Medical Centre Mannheim (DE)

Publication Details

Journal: ESMO Open
Published: 2025-11-25
DOI: https://doi.org/10.1016/j.esmoop.2025.105894
Citations: 1
Primary Topic: Cancer Genomics and Diagnostics
Type: article
Field-Weighted Citation Impact: 0.94

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

Maike Collienne, Frederik Marmé, Thomas Michaeli, Sonja Loges, Matthias Ebert, Johannes Betge, Christoph Brochhausen, Alexander Streuer, Volker Ast, Melanie Janning, Daniel Nowak, R. Lozynskyy, Fabian Siegel, Tobias Boch, Verena Haselmann, Jan Kirchhof, Michael Neumaier, Marc Sütterlin, Andreas Teufel, Eva Krieghoff‐Henning, C. Sauer, Christina Cotarelo, W-K Hofmann

November 25, 2025article en

1 citations

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

Authors

Institutions

Publication Details

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.